Zacks Research Predicts Atossa Genetics FY2027 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Equities research analysts at Zacks Research issued their FY2027 earnings estimates for shares of Atossa Genetics in a report released on Wednesday, May 13th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($3.59) for the year. The consensus estimate for Atossa Genetics’ current full-year earnings is ($4.52) per share.

Other equities research analysts also recently issued reports about the stock. Ascendiant Capital Markets cut their target price on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. HC Wainwright lifted their target price on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Weiss Ratings downgraded shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.33.

Atossa Genetics Price Performance

NASDAQ:ATOS opened at $5.16 on Thursday. The firm’s 50 day simple moving average is $5.26 and its 200 day simple moving average is $8.03. Atossa Genetics has a one year low of $3.76 and a one year high of $19.35. The company has a market cap of $44.43 million, a PE ratio of -1.61 and a beta of 1.25.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12).

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after purchasing an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. bought a new position in Atossa Genetics during the 2nd quarter worth approximately $2,468,000. Renaissance Technologies LLC raised its holdings in Atossa Genetics by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after purchasing an additional 514,175 shares during the last quarter. Geode Capital Management LLC raised its holdings in Atossa Genetics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after purchasing an additional 9,627 shares during the last quarter. Finally, State Street Corp raised its holdings in Atossa Genetics by 31.2% during the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after purchasing an additional 141,990 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.